Biohaven Ltd. (BHVN)
$10.93-4.29%Close
SELLCRISIS · day 7
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.6B
- Beta
- 3.20
- P/E (TTM)
- -2.36
- Short % float
- 22.50%
- Days to cover
- 6.4
- SI change
- -6.8%
- 1W
- -8.00%
- 1M
- -11.43%
- vs SPY 1W
- -7.02%
- vs SPY 1M
- -13.29%
Industry peers
FMP comparable companies · ranked by market cap
- ABCLBUYAbCellera Biologics Inc.$3.8BCRISISQ -6$12.37-1.90%
- CLDXSELLCelldex Therapeutics, Inc.$2.2BCRISISQ 5$27.84-1.45%
- PHVSSELLPharvaris N.V.$2.1BCRISISQ 15$30.02+0.00%
- IMNMSELLImmunome, Inc.$2.0BCRISISQ 17$17.20-2.16%
- VERASELLVera Therapeutics, Inc.$1.9BCRISISQ 20$26.74-0.19%
- XERSBUYXeris Biopharma Holdings, Inc.$1.7BBULLQ -2$9.77-4.22%
- NTLASELLIntellia Therapeutics, Inc.$1.6BRECOVERYQ 3$11.43-4.03%
- ZBIOSELLZenas BioPharma, Inc.$1.6BCRISISQ 12$24.86-1.19%
- IMCRSELLImmunocore Holdings plc$1.5BBEARQ 1$28.34+1.87%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on BHVN?
- LOPJLB’s latest quantitative signal on Biohaven Ltd. (BHVN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is BHVN in?
- Biohaven Ltd. (BHVN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Biohaven Ltd. (BHVN) do?
- Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Pha…